A Retrospective Study Evaluating Asthma Control in Patients on Fluticasone Propionate/Salmeterol Proactive Regular Dosing with a History of Uncontrolled Asthma

Overview

Journal Pulm Ther

Publisher Springer

Date 2024 Nov 9

PMID 39520649

Authors

Ahmad Izuanuddin Ismail

Irfhan Ali Hyder Ali

Chee Kuan Wong

Andrea Yu-Lin Ban

Fatimah Mz Zahrah

Li Khen Lem

Zamzurina Abu Bakar

Arvindran Alaga

Azza Omar

Azlina Samsudin

Siew Li Lai

Alap Gandhi

Affiliations

Soon will be listed here.

Abstract

Introduction: The MERIT study in Malaysia is a real-world retrospective, observational, multicenter study that evaluated asthma control in patients with uncontrolled asthma who were switched from as-needed (pro re nata [PRN]) budesonide/formoterol or inhaled corticosteroid (ICS) whenever a short-acting beta-agonist (SABA) was taken, to proactive regular dosing of fluticasone propionate/salmeterol (FP/SAL PRD).

Methods: Data from the medical records of patients who were stepped up to FP/SAL PRD were extracted retrospectively at baseline and follow-up (between 3 and 6 months after stepping up to FP/SAL PRD). The primary endpoint was the percentage of patients with improvement in asthma control assessed via the Asthma Control Test (ACT). Secondary endpoints included safety and the percentage of patients with moderate and severe exacerbations. Additionally, patient-reported use of reliever medication, systemic corticosteroids, emergency department visits, or hospitalization was also analyzed.

Results: One hundred twenty patients with uncontrolled asthma who were stepped up to FP/SAL PRD were enrolled in the study. Of these, 76 (63.3%) patients were on prior budesonide/formoterol PRN, and 44 (36.7%) were on prior ICS with SABA PRN treatment. After stepping up to FP/SAL PRD with a mean follow-up of 5.8 months, 110 (91.7%) patients achieved asthma control at the follow-up visit (p < 0.001). Similar improvements were observed regardless of prior PRN regimen. A statistically significant improvement was observed in the mean ACT score at the follow-up visit (p < 0.0001). The proportion of patients with moderate and severe exacerbations was also reduced after stepping up to FP/SAL PRD, with no adverse events reported. Over 80% of patients reported a decrease in the use of systemic corticosteroids, visits to the emergency department, or hospitalization.

Conclusion: This study highlights the effectiveness of the FP/SAL PRD treatment approach in patients with uncontrolled asthma on a PRN treatment regimen.

References

Bousquet J, Jeffery P, Busse W, Johnson M, Vignola A . Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161(5):1720-45. DOI: 10.1164/ajrccm.161.5.9903102. View

Cloutier M, Baptist A, Blake K, Brooks E, Bryant-Stephens T, DiMango E . 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020; 146(6):1217-1270. PMC: 7924476. DOI: 10.1016/j.jaci.2020.10.003. View

Doshi V, Shenoy S, Ganesh A, Lankala S, Henkle J . Near Fatal Asthma in an Inner City Population. Am J Ther. 2014; 23(6):e1375-e1380. DOI: 10.1097/MJT.0000000000000152. View

Kolmert J, Gomez C, Balgoma D, Sjodin M, Bood J, Konradsen J . Urinary Leukotriene E and Prostaglandin D Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. Am J Respir Crit Care Med. 2020; 203(1):37-53. PMC: 7781128. DOI: 10.1164/rccm.201909-1869OC. View

Lazarus S . Mild persistent asthma: is any treatment needed?. J Allergy Clin Immunol. 2006; 118(4):805-8. DOI: 10.1016/j.jaci.2006.07.044. View

Schatz M, Sorkness C, Li J, Marcus P, Murray J, Nathan R . Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006; 117(3):549-56. DOI: 10.1016/j.jaci.2006.01.011. View

Woodcock A, Bagdonas A, Boonsawat W, Gibbs M, Bousquet J, Bateman E . Improvement in asthma endpoints when aiming for total control: salmeterol/fluticasone propionate versus fluticasone propionate alone. Prim Care Respir J. 2007; 16(3):155-61. PMC: 6634212. DOI: 10.3132/pcrj.2007.00043. View

Rhee C, Moon J, Joo H, Jung J, Lee J, Min K . Summary of Korean Asthma Guideline. Tuberc Respir Dis (Seoul). 2023; 86(3):158-165. PMC: 10323208. DOI: 10.4046/trd.2023.0052. View

Denlinger L, Heymann P, Lutter R, Gern J . Exacerbation-Prone Asthma. J Allergy Clin Immunol Pract. 2019; 8(2):474-482. PMC: 6942520. DOI: 10.1016/j.jaip.2019.11.009. View

10.

Singh D, Garcia G, Maneechotesuwan K, Daley-Yates P, Irusen E, Aggarwal B . New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management. Adv Ther. 2022; 39(5):1895-1914. PMC: 9056489. DOI: 10.1007/s12325-022-02092-7. View

11.

Thompson P, Salvi S, Lin J, Cho Y, Eng P, Abdul Manap R . Insights, attitudes and perceptions about asthma and its treatment: findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong. Respirology. 2013; 18(6):957-67. DOI: 10.1111/resp.12137. View

12.

Bateman E, Reddel H, OByrne P, Barnes P, Zhong N, Keen C . As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018; 378(20):1877-1887. DOI: 10.1056/NEJMoa1715275. View

13.

OByrne P, FitzGerald J, Bateman E, Barnes P, Zhong N, Keen C . Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018; 378(20):1865-1876. DOI: 10.1056/NEJMoa1715274. View

14.

Tavakoli H, FitzGerald J, Lynd L, Sadatsafavi M . Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study. BMC Pulm Med. 2018; 18(1):33. PMC: 5809893. DOI: 10.1186/s12890-018-0598-4. View

15.

Montuschi P, Barnes P . New perspectives in pharmacological treatment of mild persistent asthma. Drug Discov Today. 2011; 16(23-24):1084-91. DOI: 10.1016/j.drudis.2011.09.005. View

16.

Chapman K, Canonica G, Lavoie K, Nenasheva N, Garcia G, Bosnic-Anticevich S . Patients' and physicians' perspectives on the burden and management of asthma: Results from the APPaRENT 2 study. Respir Med. 2022; 201:106948. DOI: 10.1016/j.rmed.2022.106948. View

17.

Schatz M, Kosinski M, Yarlas A, Hanlon J, Watson M, Jhingran P . The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009; 124(4):719-23.e1. DOI: 10.1016/j.jaci.2009.06.053. View

18.

Quirt J, Hildebrand K, Mazza J, Noya F, Kim H . Asthma. Allergy Asthma Clin Immunol. 2018; 14(Suppl 2):50. PMC: 6157154. DOI: 10.1186/s13223-018-0279-0. View

19.

Aggarwal B, Al-Moamary M, Allehebi R, Alzaabi A, Al-Ahmad M, Amin M . APPaRENT 3: Asthma Patients' and Physicians' Perspectives on the Burden and Management of Asthma in Seven Countries. Adv Ther. 2024; 41(8):3089-3118. PMC: 11263244. DOI: 10.1007/s12325-024-02900-2. View

20.

Bateman E, Busse W, Pedersen S, Bousquet J, Huang S, Zhou X . Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: A Gaining Optimal Asthma Control (GOAL) study reanalysis. Ann Allergy Asthma Immunol. 2019; 123(1):57-63.e2. DOI: 10.1016/j.anai.2019.04.018. View